Genmab A/S ADS
GMAB · Nasdaq
- $57.29
- $35.25B
- Open
- —
- —
- $55.68 - $58.19
- $23.62 - $59.97
- —
- —
- 6.25M
About Genmab A/S ADS
Genmab is a biotechnology company that discovers and develops cancer medicines, including antibody-based therapies and antibody-drug conjugates. Its pipeline includes petosemtamab and Rina-S, and its development work includes combinations with medicines such as pembrolizumab. Genmab also works with partners: it and Incyte are collaborating on a clinical trial of a combination therapy for KRAS G12D-mutated metastatic colorectal cancer. The company says it is seeking to grow through medicines it owns or co-develops. The supplied evidence does not provide a segment revenue breakdown, commercial sales scale, or a detailed customer mix.
Notable Price Movement
- Oct 26-30$56.4929.00%
GMAB rose 41.23% across the supplied $40.00-to-$56.49 window, with the decisive move coming on Wednesday, Oct. 28. After closing at $44.69 on Monday and virtually unchanged at $44.67 Tuesday, the stock jumped to $57.29 on 29.3 million shares, following Genmab’s positive Phase III update for petosemtamab plus pembrolizumab in first-line recurrent or metastatic head-and-neck cancer and reports of three positive Phase III readouts. The stock eased 80 cents to $56.49 Thursday, retaining nearly all of Wednesday’s surge. Biotech peers also rose, but the exceptional volume and gain coincided with Genmab-specific trial news.
